Category - Developments

Developments

Fluidigm introduces new immune profiling system

Fluidigm’s (NASDAQ:FLDM) new immune profiling system, Maxpar Direct, quantifies immune cell populations with automated five-minute results reporting. Maxpar Direct uses a single-tube workflow to profile 37 different...

March 28, 2019

Developments

Neuronetics receives Japanese reimbursement for NeuroStar’s TMS Therapy

Transcranial magnetic stimulation (TMS) pioneer, Neuronetics (NASDQ:STIM), received reimbursement approval from Japan’s Central Social Insurance Medical Council for its NeuroStar Advanced Therapy for the treatment...

March 28, 2019

Developments

Titan Pharma in pact with AppianRx for comprehensive Probuphine patient support services

Titan Pharmaceuticals (NASDAQ:TTNP) executed a service agreement with AppianRx, a specialty healthcare solutions company, to provide a full suite of patient support services related to Titan’s Probuphine implant, a...

March 28, 2019

Developments

Lutronic Vision retains retina expert to lead R:GEN pilot AMD clinical study

Closely-held Lutronic Vision retained professor Robyn Guymer, a world-renowned age-related macular degeneration (AMD) expert and key opinion leader, to serve as the principal investigator for its planned pilot clinical...

March 27, 2019

Developments

BeyondSpring to present promising new strategy for cancer treatment with Plinabulin

BeyondSpring (NASDAQ: BYSI) will present a promising new strategy for cancer treatment involving the ability of its lead asset, Plinabulin, to positively shift the balance of macrophage phenotypes for a beneficial anti...

March 26, 2019

Developments

BeyondSpring advancing patient targeting strategies for lead asset, Plinabulin

BeyondSpring (NASDAQ: BYSI) will present novel data relevant to predictive biomarkers for patient selection for its lead asset, Plinabulin, at the 2019 American Association for Cancer Research (AACR) annual meeting in...

March 25, 2019

Developments

Gritstone doses first patient in personalized immunotherapy trial

Gritstone Oncology (NASDAQ:GRTS) dosed the first patient with its personalized immunotherapy candidate targeting the patient’s tumor-specific neoantigens, called GRANITE-001. The Phase 1/2 clinical study is evaluating...

March 22, 2019

Developments

Biogen discontinues two Phase 3 trials of aducanumab in Alzheimer’s disease

Biogen (NASDAQ:BIIB) and partner Eisai are discontinuing two global Phase 3 trials to evaluate the efficacy and safety of aducanumab in Alzheimer’s disease (AD). Aducanumab is a monoclonal antibody designed to slow AD...

March 21, 2019

Developments

RTI Surgical enrolls first patient in 3D-printed spinal fusion device study

RTI Surgical (NASDAQ:RTIX) has enrolled the first patient in a clinical trial testing the safety and performance of its Fortilink interbody fusion device. Fortilink is designed to promote spinal fusion after surgery...

March 20, 2019

Developments

Altimmune’s NasoVAX provides 100% seroprotection more than one year after vaccination

Altimmune’s (NASDAQ:ALT) intranasal influenza vaccine, NasoVAX, demonstrated a seroprotective antibody response in all subjects who received the vaccine more than one year ago. The Phase 2a trial of NasoVAX was...

March 20, 2019

Category - Developments

Subscribe